US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

1.040 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Why Did Allarity Therapeutics Stock Double In Value Today? ↗
Via Stocktwits
News headline image
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks have an unusual volume in today's session ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Check out the stocks that are attracting the most attention and driving market activity. ↗
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
News headline image
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
Via AB Newswire
Topics Government
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >